title: Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
authors.affiliation: Department of Radiology and Biomedical Imaging, University of California-San Francisco, UCSF Mail Code 2532, Byers Hall Room #303, 1700 4th Street, San Francisco, CA 94158-0223, USA. emma.essock-burns@radiology.ucsf.edu
authors.forename: Emma
authors.initials: E
authors.lastname: Essock-Burns
authors.forename: Janine M
authors.initials: JM
authors.lastname: Lupo
authors.forename: Soonmee
authors.initials: S
authors.lastname: Cha
authors.forename: Mei-Yin
authors.initials: MY
authors.lastname: Polley
authors.forename: Nicholas A
authors.initials: NA
authors.lastname: Butowski
authors.forename: Susan M
authors.initials: SM
authors.lastname: Chang
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Nelson
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000532:radiotherapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018450:Disease Progression; D005909:Glioblastoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007211:Indoles / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D010477:Perfusion; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007211:Indoles; D003606:Dacarbazine; C504878:enzastaurin; D000077204:Temozolomide